Vis enkel innførsel

dc.contributor.authorHoksrud, Aasne Fenne
dc.contributor.authorBahr, Roald
dc.date.accessioned2012-09-28T11:50:26Z
dc.date.available2012-09-28T11:50:26Z
dc.date.issued2011-08-12
dc.identifierSeksjon for idrettsmedisinske fag / Department of Sports Medicine
dc.identifier.citationAmerican Journal of Sports Medicine. 2011, 39 (11), 2377-2380no_NO
dc.identifier.issn0363-5465
dc.identifier.urihttp://hdl.handle.net/11250/170936
dc.descriptionI Brage finner du siste tekst-versjon av artikkelen, og den kan inneholde ubetydelige forskjeller fra forlagets pdf-versjon. Forlagets pdf-versjon finner du på sagepub.com: http://dx.doi.org/10.1177/0363546511417097 / In Brage you'll find the final text version of the article, and it may contain insignificant differences from the journal's pdf version. The original publication is available at sagepub.com: http://dx.doi.org/10.1177/0363546511417097no_NO
dc.description.abstractBackground: A randomized controlled study has shown good clinical results after treatment with sclerosing injections into the area with neovessels in patients with patellar tendinopathy, but no study has investigated medium- or long-term outcomes. Purpose: This study investigates the effect of sclerosing treatment 44 months (range, 42-47 months) after start of treatment. Study Design: Case series; Level of evidence, 4. Methods: Patients with a diagnosis of jumper’s knee and neovascularization corresponding to the painful area were recruited and treated with ultrasound-guided sclerosing injections using polidocanol. Primary outcome was Victorian Institute of Sport Assessment (VISA) score, which was recorded before the start of treatment, after 12 months, and 44 months after the start of the study period. Results: Twelve of the 29 patients (14 tendons) who were followed up at 44 months had undergone arthroscopic surgery after sclerosing treatment, either to the patellar tendon (n = 6) or for other intra-articular lesions (n = 8). For patients who did not receive additional treatment after the sclerosing injections (n = 23 tendons), VISA score was 55 (range, 28-71) at baseline and 81 (range, 39-100) at 12-month follow-up (P < .001 vs baseline).Their VISA score at 44 months’ follow-up was 89 (range, 73-100; P = .047 vs 12 months). For patients who went through arthroscopic tendon surgery, VISA score was 53 (range, 39-71) at baseline and 71 before surgery (range, 48-98; P = .14 vs baseline). Their VISA score at 44 months was 91 (range, 76-100; P = .0.16 vs 12 months; P = .005 vs baseline). For patients who went through non–tendon surgery, VISA score was 45 (range, 15-69) at baseline and 57 (range, 32-95) before surgery (P = .29 vs baseline). Their VISA score at 44 months was 92 (range, 72-100; P = .006 vs before surgery; P < .001 vs baseline). Conclusion: Sclerosing treatment with polidocanol was effective for the majority of the patients. Nevertheless, one-third elected to seek additional treatment through arthroscopic surgery during the 44-month follow-up period.no_NO
dc.language.isoengno_NO
dc.publisherSAGEno_NO
dc.subjectjumper's kneeno_NO
dc.subjectpolidocanolno_NO
dc.subjectcolor Dopplerno_NO
dc.subjecttendonno_NO
dc.titleUltrasound-guided sclerosing treatment in patients with patellar tendinopathy (jumper's knee): 44 month follow-upno_NO
dc.typeJournal articleno_NO
dc.typePeer reviewedno_NO
dc.subject.nsiVDP::Social science: 200::Social science in sports: 330no_NO
dc.subject.nsiVDP::Medical disciplines: 700::Clinical medical disciplines: 750no_NO
dc.subject.nsiVDP::Medical disciplines: 700::Sports medicine: 850no_NO
dc.source.pagenumber2377-2380no_NO
dc.source.volume39no_NO
dc.source.journalAmerican Journal of Sports Medicineno_NO
dc.source.issue11no_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel